Medically reviewed by Dr. Hyun Joon Lee, MD. Board-certified in Family Medicine, Integrative Holistic Medicine, and Obesity Medicine. Founder and Medical Director, SeeBeyond Medicine.
These medications were studied as long-term therapy
Semaglutide and tirzepatide are prescribed for long-term weight management. The Wegovy prescribing information describes semaglutide as an adjunct to a reduced-calorie diet and increased physical activity, indicated to reduce excess body weight and maintain that reduction long term (FDA label).
That phrase, maintain long term, is doing quiet work. The trials that established these drugs kept participants on them, and the trials that stopped the drug were designed to measure what happens next.
Those withdrawal studies are the most useful reading available to anyone planning an exit.
What the withdrawal trials reported
STEP 1 randomized 1,961 adults with obesity, or with overweight plus a weight-related condition and no diabetes, to 68 weeks of weekly semaglutide 2.4 mg alongside lifestyle intervention. Mean weight loss on semaglutide reached 17.3%.
An extension followed 327 of those participants for a year after treatment and lifestyle support stopped. They regained two-thirds of their prior weight loss, and cardiometabolic markers moved back in step with the weight (Wilding and colleagues, Diabetes, Obesity and Metabolism, 2022).
STEP 4 tested the same question inside a randomized design. After a 20-week run-in on semaglutide, participants who continued lost a further 7.9% on average, while those switched to placebo regained 6.9% of body weight by week 68 (Rubino and colleagues, JAMA, 2021).
Tirzepatide behaved the same way. SURMOUNT-4 gave 36 weeks of open-label treatment, then randomized participants to continue or switch to placebo for 52 weeks, and withdrawal produced substantial regain while continued treatment maintained and added to the reduction (Aronne and colleagues, JAMA, 2024).
Regain follows a curve, not a cliff
Pooling those trials changes the picture slightly. A systematic review and nonlinear meta-regression of six randomized trials, covering 3,236 participants, modelled the shape of regain after cessation.
One year after stopping, roughly 60% of the weight lost during treatment had returned. Extrapolated further, the curve flattened at about three-quarters of the lost weight (eClinicalMedicine, 2026).
Read that carefully, because it cuts both ways. Most of the loss goes, and the modelled plateau still sits below where people started.
Why the weight returns
The STEP 1 investigators drew the obvious conclusion from their own extension data. The findings confirm the chronicity of obesity and suggest that ongoing treatment is required to maintain improvements in weight and health.
Appetite regulation is the mechanism these drugs act on, and that regulation resumes its previous behavior once the drug clears. Hunger returns, portions drift upward, and the body defends its former weight.
Nothing in that sequence is a character failure. It is the same reason blood pressure rises again when an antihypertensive is stopped.
Where a lower maintenance dose fits
Not every exit is a full stop. Some patients continue at a reduced dose rather than discontinuing, which keeps some appetite support in place while lowering exposure and cost.
The evidence base here is thinner than it looks. The withdrawal trials compared continuing the full dose against placebo, so they do not tell you how a specific reduced dose performs over years.
That makes dose reduction a clinical decision rather than a formula. It belongs to the physician who knows your history, your labs, and how you responded on the way up, which is why no taper schedule appears in this article.
What actually carries the result afterward
Body composition is the variable most people ignore until it matters. Reviews of GLP-1 body-composition data report that fat mass falls more than lean mass, while lean tissue still accounts for a meaningful share of total weight lost.
Lean tissue is what sets resting energy expenditure. Losing it quietly lowers the number of calories you can eat at your new weight, which makes regain easier and maintenance harder.
The countermeasures are unglamorous and well described. Protein intake above roughly 1.2 grams per kilogram of body weight per day, distributed across meals, combined with structured resistance training (Metabolites, 2026).
Building those habits during treatment, while appetite is suppressed and training feels manageable, is the point. They are what remains when the injection stops.
A maintenance plan worth having before you stop
- Have the exit conversation at the start of treatment, not in the final month, so the plan has time to be built.
- Track body composition rather than scale weight alone, so lean tissue loss is visible while it can still be corrected.
- Set a protein target and a resistance-training schedule you can hold on a normal week, then keep both through the taper.
- Re-check the metabolic markers that improved during treatment, since those gains track weight regain closely.
- Agree in advance on what degree of regain triggers a clinical review rather than a private struggle.
- Keep a follow-up cadence after the last dose, because the steepest part of the regain curve is the first year.
Testing tells you which of those levers matters most for you. Test, don't guess.
Key Takeaways
- Published withdrawal extensions of the major trials reported substantial regain after the medication stopped.
- Regain reflects the return of appetite signaling, which means obesity behaves like a chronic condition rather than a finished project.
- Some patients move to a lower maintenance dose instead of stopping outright, which is a clinical decision.
- Muscle mass, protein intake, and training built during treatment are what carry the result afterward.
Related Resources
Start with our GLP-1 medical weight loss guide for candidacy, dosing structure, expected results, and monitoring.
For the treatment side, read about physician-supervised GLP-1 weight loss therapy, tirzepatide therapy, and the wider medical weight loss program.
Maintenance work usually runs through nutrition counseling and individual optimal nutrition profile testing. Patients whose symptoms point elsewhere may also review hormone replacement therapy during the same visit.
The month you stop is the wrong month to start planning. Maintenance is a system you build while the medication is still doing the heavy work.
SeeBeyond Medicine runs weight management under a physician board-certified in Obesity Medicine, at our Scarsdale, NY office in Westchester County and our Greenwich, CT office in Fairfield County.
You can schedule a consultation to review an exit plan, or browse physician-formulated supplements that support the nutrition side of maintenance.
This article is for general education and does not replace a medical evaluation. Treatment decisions depend on your history, medications, and lab work. Speak with a qualified clinician before starting, stopping, or changing any therapy.
